SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.85% Stake in Voyager Therapeutics

Armistice Capital, LLC and Steven Boyd have jointly disclosed a beneficial ownership of 9.85% in Voyager Therapeutics, Inc., holding 5,436,000 shares of common stock as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed an Amendment No. 4 to Schedule 13G regarding their beneficial ownership in Voyager Therapeutics, Inc.
• As of March 31, 2025, the Reporting Persons beneficially own an aggregate of 5,436,000 shares of Voyager Therapeutics, Inc. common stock.
• This ownership represents 9.85% of the issuer's common stock outstanding.
• The percentage is calculated based on 55,206,885 shares outstanding as of March 3, 2025, as reported in Voyager Therapeutics' Form 10-K filed on March 11, 2025.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares, and exercises shared voting and dispositive power over these securities.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is also deemed to beneficially own the shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or information that would indicate a positive or negative sentiment regarding the issuer's performance or prospects. It simply reports a stake.

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by an investment firm in a biotechnology company, Voyager Therapeutics, Inc. Such disclosures are common in the investment landscape, reflecting institutional interest in specific sectors or companies. It doesn't provide specific insights into broader industry trends beyond the general interest in the biotech sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.85% stake by Armistice Capital and Steven Boyd provides transparency regarding a major institutional investor's position, which can influence market perception and potentially signal confidence or strategic interest in Voyager Therapeutics, Inc.

Key Dates

Keywords

Voyager Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, investment management, biotechnology, pharmaceuticals, SEC filing